Compare CWT & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | OLMA |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.0B |
| IPO Year | 1997 | 2020 |
| Metric | CWT | OLMA |
|---|---|---|
| Price | $44.83 | $14.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $54.50 | $41.13 |
| AVG Volume (30 Days) | 345.5K | ★ 1.5M |
| Earning Date | 06-03-2026 | 04-15-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $963,695,000.00 | N/A |
| Revenue This Year | $9.78 | N/A |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $20.50 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $2.86 |
| 52 Week High | $51.23 | $36.26 |
| Indicator | CWT | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 20.31 |
| Support Level | $44.23 | $4.35 |
| Resistance Level | $47.01 | $27.38 |
| Average True Range (ATR) | 1.10 | 1.35 |
| MACD | -0.24 | -0.95 |
| Stochastic Oscillator | 41.70 | 2.29 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.